Your browser doesn't support javascript.
loading
Binding blockade between TLN1 and integrin ß1 represses triple-negative breast cancer.
Zhang, Yixiao; Sun, Lisha; Li, Haonan; Ai, Liping; Ma, Qingtian; Qiao, Xinbo; Yang, Jie; Zhang, Hao; Ou, Xunyan; Wang, Yining; Chen, Guanglei; Xue, Jinqi; Zhu, Xudong; Zhao, Yu; Yang, Yongliang; Liu, Caigang.
Afiliação
  • Zhang Y; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
  • Sun L; Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China.
  • Li H; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
  • Ai L; Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China.
  • Ma Q; Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China.
  • Qiao X; School of Bioengineering, Dalian University of Technology, Dalian, China.
  • Yang J; Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China.
  • Zhang H; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
  • Ou X; Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China.
  • Wang Y; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
  • Chen G; Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China.
  • Xue J; Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China.
  • Zhu X; Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China.
  • Zhao Y; Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China.
  • Yang Y; Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China.
  • Liu C; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Elife ; 112022 03 14.
Article em En | MEDLINE | ID: mdl-35285795
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Mama Triplo Negativas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Elife Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Mama Triplo Negativas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Elife Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China